Wednesday

Pharma Webinars

Oct. 28th

1

11:00 am – 12:15 pm ET

The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowded and competitive.

Category: Chronic Diseases

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

WHO IS SPEAKING

Rinvoq_logo

Representative of
AbbVie Inc.

Douglas_Schlichting_Eli_Lilly_Pharma_Web_1

Douglas Schlichting, RN, PhD
Development Director
Immunology Product Development – baricitinib rheumatoid arthritis and COVID-19
Eli Lilly and Company

David_Platt_Novartis_Pharma_Web_1

David Platt, MD
Vice President, Medical Unit Head
Cardiovascular, Renal & Metabolism Medical Unit  
Novartis Pharmaceuticals Corporation

Vyndaqel_logo

Representative of
Pfizer Inc.

Adhansia_logo

Representative of
Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P.

Yupelri_logo

Representative of
Theravance Biopharma, Inc.

Eric_Pearlman_Eli_Lilly__BioTech_Web_1_Pharma_Web_1

Eric M Pearlman
Senior Medical Director-Neuroscience, US Medical Affairs

Eli Lilly and Company

Rinvoq_logo
Olumiant_logo
Entresto_logo
Vyndaqel_logo
Adhansia_logo
Yupelri_logo
Reyvow_logo

2

12:30 pm – 1:45 pm ET

What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation?

Category: Solid Tumor Cancers

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

WHO IS SPEAKING

Mimi_Huizinga_Novartis_Pharma_Web_2_3

Mimi Huizinga, MD
Vice President and Head, US Oncology Medical
Novartis

Dr_Marc_Fellous_Bayer_Pharma_Web_2

Dr. Marc Fellous
Global Medical Affairs Head
Bayer

Rozlytrek_logo

Representative of
Genentech, a member of the Roche Group

Sam_Spigelman_Balversa_Pharma_Web_2

Sam Spigelman, MD
Senior Global Medical Affairs Leader
Janssen Research & Development, LLC

Sabine_Brookman-May_Erleada_Pharma_Web_2

Sabine Brookman-May, MD, PhD
Executive Medical Director, Late Development, Solid Tumor
Janssen Research & Development, LLC

Lorbrena_logo

Representative of
Pfizer Inc.

Lutathera_logo
Darolutamide_logo
Rozlytrek_logo
Balversa_logo
Erleada_logo
Piqray_logo
Lorbrena_logo
Vitrakvi_logo

3

2:00 pm – 3:00 pm ET

Are there common links in advancing research on hematologic cancers and other rare diseases associated with uncontrolled vascular system inflammation, such as sickle cell anemia?

Category: Hematologic cancers and other rare diseases

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

WHO IS SPEAKING

Dr_Ramon_Tiu_Astellas_Pharma_Web_3

Ramon V. Tiu, M.D.
Executive Medical Director, Astellas Pharma Global Development
Global Medical Leader, Gilteritinib Program
Astellas Pharma Inc.

Xpovio_logo

Representative of
Karyopharm Therapeutics Inc.

Mimi_Huizinga_Novartis_Pharma_Web_2_3

Mimi Huizinga, MD
Vice President and Head, US Oncology Medical
Novartis

Epidiolex_logo

Representative of
GW Pharmaceuticals plc & Greenwich Biosciences Inc.

Gamifant_logo

Representative of
Sobi, Inc.

Xospata_logo
Xpovio_logo

Representative of
Karyopharm Therapeutics Inc.

Adakveo_logo
Epidiolex_logo

Representative of
GW Pharmaceuticals plc & Greenwich Biosciences Inc.

Gamifant_logo

Representative of
Sobi, Inc.


4

3:00 pm – 4:00 pm ET

Will the coronavirus pandemic finally lead to an upswing in R&D to tackle neglected areas like antibiotic resistance, zoonotic transmission of pathogens and a more globally-coordinated approach to infectious diseases overall?

Category: Infectious diseases and reproductive health

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG

WHO IS SPEAKING

Mark_Sullivan_MDGH_Pharma_Web_4

Mark Sullivan
Founder and Managing Director
Medicines Development for Global Health,

Amanda_Paschke_Merck_Pharma_Web_4

Amanda Paschke, MD, MSCE
Executive Director
Global Clinical Development
Merck & Co., Inc.

1562680614Final_PC_Color_Logo-RGB

Representative of
Population Council and TherapeuticsMD

1563901225SIGA-Full_Logo-3337x1675-500dpi

Representative of
SIGA Technologies, Inc.

Daniel_Everitt_TB_Alliance_Pharma_Web_4

Daniel Everitt, MD
Vice President and Chief Medical Officer
TB Alliance

1564116849MD_Logo
recarbrio-logo
1562680614Final_PC_Color_Logo-RGB
1563901225SIGA-Full_Logo-3337x1675-500dpi
1595340100TBA_logo_2-color

Stay tuned: new developments are on the way